LifeStance Health Director Robert Bessler Trims Equity Position

Robert Bessler, a member of the Board of Directors at LifeStance Health Group (NASDAQ: LFST), executed multiple open-market sales of company stock on April 23 and 24, 2026. According to SEC Form 4 filings, Bessler sold 69,899 shares at a weighted average price of $7.04, totaling approximately $492,000. Despite the sale, Bessler maintains a substantial stake in the company. Following the transactions, he continues to hold 57,619 shares directly and approximately 2.7 million shares indirectly. The scale of the sale represents only 2.47% of his total holdings and is consistent with his historical trading cadence. The divestment follows a period of robust operational performance for the outpatient mental health provider. LifeStance reported 2025 full-year revenue of $1.4 billion, representing a 14% increase year-over-year. More significantly, the company achieved a dramatic bottom-line turnaround, posting a net income of $9.7 million for 2025, compared to a net loss of $57.4 million in 2024. Looking forward, LifeStance expects 2026 revenue to reach approximately $1.6 billion, indicating continued growth. While the stock reached a 52-week high of $8.09 in February, the current forward price-to-sales ratio of two suggests a valuation that has become elevated relative to historical norms. Market analysts generally view this activity as routine portfolio management rather than a signal of internal distress, given the director's massive remaining equity position and the company's improving financial trajectory.